|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
135,340,000 |
Market
Cap: |
553.54(M) |
Last
Volume: |
11,363,101 |
Avg
Vol: |
11,332,083 |
52
Week Range: |
$2.65 - $5.59 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Co.'s primary program, molgramostim nebulizer solution is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor and is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. Molgramostim nebulizer solution is administered once daily by inhalation via a nebulizer, the eFlow® Nebulizer System. The eFlow® Nebulizer System is a reusable electronic inhalation system. Molgramostim was also being investigated in cystic fibrosis (CF) and non-CF patients for the treatment of nontuberculous mycobacterial lung infection, a lung disorder.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
3,339,830 |
4,023,225 |
Total Buy Value |
$0 |
$0 |
$10,019,035 |
$11,106,809 |
Total People Bought |
0 |
0 |
11 |
12 |
Total Buy Transactions |
0 |
0 |
11 |
42 |
Total Shares Sold |
0 |
187,843 |
187,843 |
187,843 |
Total Sell Value |
$0 |
$885,322 |
$885,322 |
$885,322 |
Total People Sold |
0 |
3 |
3 |
3 |
Total Sell Transactions |
0 |
3 |
3 |
3 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Neville Robert N |
Chief Executive Officer |
|
2018-06-11 |
4 |
AS |
$12.01 |
$21,513 |
D/D |
(1,791) |
487,956 |
|
- |
|
Neville Robert N |
Chief Executive Officer |
|
2018-06-11 |
4 |
D |
$11.43 |
$60,030 |
D/D |
(5,252) |
489,747 |
|
- |
|
Neville Robert N |
Chief Executive Officer |
|
2018-06-11 |
4 |
OE |
$0.65 |
$60,028 |
D/D |
92,351 |
494,999 |
|
- |
|
Jouhikainen Jaakko Taneli |
See Remarks |
|
2018-06-08 |
4 |
AS |
$12.11 |
$31,950 |
D/D |
(2,638) |
207,688 |
|
- |
|
Lowrance David L |
Chief Financial Officer |
|
2018-06-08 |
4 |
AS |
$12.13 |
$8,187 |
D/D |
(675) |
23,080 |
|
- |
|
Neville Robert N |
Chief Executive Officer |
|
2018-06-08 |
4 |
AS |
$12.13 |
$33,212 |
D/D |
(2,737) |
402,648 |
|
- |
|
Pikover Yuri |
Director |
|
2018-03-29 |
4 |
B |
$9.00 |
$33,603 |
D/D |
3,734 |
153,734 |
2.39 |
- |
|
Lowrance David L |
Chief Financial Officer |
|
2018-02-15 |
4 |
AS |
$12.70 |
$90,129 |
D/D |
(7,000) |
23,755 |
|
- |
|
Jouhikainen Jaakko Taneli |
See Remarks |
|
2018-02-15 |
4 |
AS |
$12.75 |
$321,320 |
D/D |
(25,000) |
210,326 |
|
- |
|
Neville Robert N |
Chief Executive Officer |
|
2018-02-15 |
4 |
AS |
$12.84 |
$323,173 |
D/D |
(25,000) |
405,385 |
|
- |
|
Lowrance David L |
Chief Financial Officer |
|
2018-01-02 |
4 |
D |
$15.06 |
$48,779 |
D/D |
(3,239) |
30,755 |
|
- |
|
Lowrance David L |
Chief Financial Officer |
|
2018-01-02 |
4 |
OE |
$1.51 |
$48,160 |
D/D |
31,894 |
33,994 |
|
- |
|
Pikover Yuri |
Director |
|
2017-10-27 |
4 |
B |
$7.85 |
$392,500 |
D/D |
50,000 |
150,000 |
2.39 |
- |
|
Zambon Spa |
10% Owner |
|
2017-06-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,693,540 |
|
- |
|
Neville Robert N |
Chief Executive Officer |
|
2017-06-07 |
4 |
B |
$4.75 |
$248,188 |
D/D |
52,250 |
430,385 |
2.81 |
- |
|
Ramsay David A |
Director |
|
2017-06-07 |
4 |
B |
$4.75 |
$99,750 |
D/D |
21,000 |
22,428 |
2.39 |
- |
|
Pikover Yuri |
Director |
|
2017-06-07 |
4 |
B |
$4.75 |
$475,000 |
D/D |
100,000 |
100,000 |
2.39 |
- |
|
Mccracken Joseph S |
Director |
|
2017-06-07 |
4 |
B |
$4.75 |
$248,188 |
D/D |
52,250 |
59,866 |
2.39 |
- |
|
Jouhikainen Jaakko Taneli |
See Remarks |
|
2017-06-07 |
4 |
B |
$4.75 |
$49,875 |
D/D |
10,500 |
235,326 |
2.74 |
- |
|
Lowrance David L |
Chief Financial Officer |
|
2017-06-07 |
4 |
B |
$4.75 |
$9,975 |
D/D |
2,100 |
2,100 |
2.74 |
- |
|
Pauls Matthew |
See Remarks |
|
2017-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
650 |
650 |
|
- |
|
Ramsay David A |
Director |
|
2017-04-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,142 |
23,570 |
|
- |
|
Serenova A/s |
10% Owner |
|
2017-04-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,965,400 |
|
- |
|
Mccracken Joseph S |
Director |
|
2017-04-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,616 |
|
- |
|
Jouhikainen Jaakko Taneli |
See RemarksOfficer |
|
2017-04-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
224,826 |
|
- |
|
239 Records found
|
|
Page 7 of 10 |
|
|